Next generation therapeutics

Home / R&D / Next generation therapeutics


We are constantly pushing the boundaries of science to deliver life-changing medicines which will have the greatest and swiftest impact on the diseases we are aiming to treat, prevent, modify and in the future, even cure. It is only by enhancing our understanding of disease biology and uncovering new ways of targeting the drivers of disease that we will create the next generation of therapeutics across our main therapy areas in Oncology, 心血管,肾脏和代谢, and Respiratory and Immunology.

We are already leveraging the rapid advancements in science and technology to create new therapeutics, such as cell-based therapy, antibody therapeutics, 以及基于核苷酸的疗法, 对于以前被认为很困难的疾病机制, if not impossible, to target.1 Additionally, 澳门葡京赌博游戏正致力于整合候选药物及其与靶标相互作用的知识, the pathophysiology of disease and the delivery system in order to design advanced delivery technologies.每一个新的见解和每一条新的信息都使澳门葡京赌博游戏更接近创造更好, 为患者提供更先进、更有效的治疗.

Partnering with collaborators across the world is helping our scientists pioneer new approaches to drug discovery. In fact, 30% 澳门葡京赌博游戏早期的管道现在包括新的药物模式,包括寡核苷酸, mRNA and Anticalin® proteins.

next-generation pipeline

Selecting the right target with a strong link to the drivers of disease remains the most important decision we make in the drug discovery process. Once this target is selected, we now have a toolbox of traditional and innovative molecules which we can use to enable us to target the novel biology. 您可以在下面探索澳门葡京赌博游戏的模态工具箱.


Small molecules

Small molecules

We have a long history of discovering and developing orally delivered small molecule medicines by harnessing innovative approaches to drug design and delivery. Small molecules can be designed to engage biological targets by various modes of action and act both intracellularly and extracellularly. Their distribution can further be tailored to allow for systemic exposure with or without brain penetration. Click on the tiles below to read more about our research from traditional small molecules which have long been a cornerstone of our business, to ground-breaking, 新的小分子方法,如PROTACs和环硅酸锆.

Peptide or protein therapeutics

Peptide or protein therapeutics

通过澳门葡京赌博游戏在蛋白质工程方面的长期专业知识, 澳门葡京赌博游戏正在推进传统和新型的蛋白质和肽疗法. 因为蛋白质是大分子, they are generally not cell permeable and have traditionally been restricted to extracellular targets and injectable administration routes. 多肽是一种较小的蛋白质疗法. 它们通常发育得很小, 细胞外目标的特异性和高选择性配体.

Through various collaborations, we are exploring the development of not only traditional protein therapeutics and peptides but also potentially innovative therapies such as Anticalin® proteins and bicyclic peptides. 点击下面的图片阅读更多关于这些新型药物模式的信息.

Nucleotide-based therapeutics & gene therapy

Nucleotide-based therapeutics & gene therapy

基因组学的最新进展已经带来了无数潜在的新药物靶点, 基于核苷酸的治疗方法有机会对疾病产生真正的影响. We are exploring a number of nucleotide-based modalities from oligonucleotides and RNA-based therapies to using CRISPR/Cas9 as a potential therapeutic tool. 点击下面的图片阅读更多关于这些新型药物模式的信息.


澳门葡京赌博游戏取得的每一项进步背后,都有一群敬业的科学家. 了解更多澳门葡京网赌游戏在药物发现前沿工作的研究人员的信息: 


1. Valeur E, Guéret SM, Adihou H et al. 药物发现中挑战靶点的新模式. Angewandte Chemie. 2017. 56(35): 10294-10323.

2. Ashford M. Drug Deliv Transl Res. 2020 Oct 6. doi: 10.1007/s13346-020-00858-6. Online ahead of print. 

Veeva ID: Z4-58111